Role of Aberrant Glycosylation of IgA1 Molecules in the Pathogenesis of IgA Nephropathy

J. Mestecky a, b, g M. Tomana b Z. Moldoveanu a B.A. Julian a, b H. Suzuki a, f K. Matousovic a, g M.B. Renfrow c L. Novak d R.J. Wyatt e J. Novak a

Departments of a Microbiology, b Medicine, c Biochemistry/Molecular Genetics, and d Pathology, University of Alabama at Birmingham, Birmingham, Ala., and e University of Tennessee Health Science Center, Memphis, Tenn., USA; f Juntendo University School of Medicine, Tokyo, Japan; g Charles University, Schools of Medicine, Prague and Pilsen, Czech Republic

Key Words
IgA nephropathy · Glycosylation · Immune complexes · Glycosyltransferases

Abstract
Studies of the properties of immune complexes (IC) in the circulation, urine, and mesangium of IgA nephropathy (IgAN) patients have provided data relevant to the pathogenesis of this disease. IC contain predominantly polymeric IgA1 molecules which are deficient in galactose (Gal) residues on O-linked glycan chains in the hinge region (HR) of their heavy (H) chains. As a result of this aberrancy, a novel antigenic determinant(s) involving N-acetylgalactosamine (GalNAc) and perhaps sialic acid (SA) of O-linked glycans is generated and recognized by naturally occurring GalNAc-specific antibodies. Thus, IC in IgAN consist of Gal-deficient IgA1 molecules as an antigen, and GalNAc-specific IgG and/or IgA1 as an antibody. IgG antibodies to Gal-deficient IgA1 are probably induced by cross-reactive microbial antigens; they are present at variable levels not only in humans with or without IgAN but also in many phylogenetically diverse vertebrate species. Incubation of human mesangial cells with IC from sera of IgAN patients indicated that stimulation of cellular proliferative activity was restricted to the large (>800 kDa) complexes. These findings suggest that experimental approaches that prevent the formation of large Gal-deficient IgA1-IgG IC may be applied ultimately in an immunologically mediated therapy.

Introduction

IgA nephropathy (IgAN), also called Berger disease after its discoverer, was described in 1968 [1] and is immunohistochemically characterized by the co-deposition of IgA and IgG in the glomerular mesangium. Although since 1968 hundreds of papers, several monographs, and proceedings from 11 International Symposia have been published, this most common form of primary glomerulonephritis continues to provide considerable challenge not only to nephrologists, but also to human geneticists, immunologists, biochemists, and pharmacologists [2–4].

The purpose of this paper is to summarize contributions of our laboratory to the understanding of the pathogenesis of IgAN. After almost two decades of studies on the structure and function of human secretory and serum IgA, our laboratory became interested in IgAN in the mid-1980s through stimulating interactions with local nephrologists, Drs. Galla and Julian, and this renal disease has remained one of the top priorities of our research.
Characterization of IgA1 Mesangial Deposits and Circulating Immune Complexes (CIC)

In humans, IgA occurs in two subclasses biochemically distinct in their primary structures, particularly in the hinge region (HR) of heavy (H) chains (see below). Furthermore, IgA1 and IgA2 differ in the content and composition of H-chain-associated glycans, sensitivities to bacterial proteases, distribution in various body fluids, tissue localization of plasma cells, metabolism, and specificities to various types of antigens [5–7].

After the initial confusion with respect to the IgA subclass association, it is now firmly established that IgA1 and not IgA2 represents the exclusive IgA subclass in mesangial deposits [8, 9]. Further immunohistochemical studies indicated that IgA1 is deposited in the polymeric (p) form, as determined by the staining for J chain exclusively found in plgA or IgM [7], and with the currently unexplained dominance of light (L) chains of the λ isotype [10]. Complement component C3 and IgG and IgM represent the most frequent co-deposits [9]. These findings suggested that the mesangial IgA1 deposits are composed of ICs; however, it was not clear whether such ICs are formed in situ or are derived from the circulation. Many studies, including those from our laboratory [11–13], convincingly documented the parallelism in composition of CIC and mesangial deposits: IgA1 as the exclusive IgA subclass, C3, and IgG or, at low levels, IgM; in comparison, IgA2-containing CIC were detectable only at low levels in a very few patients [9, 11]. Determinations of molecular masses of CIC by sucrose gradient ultracentrifugation revealed a considerable degree of heterogeneity with sedimentation constants ranging from 11 to 19S [11]. This finding proved to be an important point with respect to the restricted nephritogenicity of CIC, as determined by cultures of human mesangial cells with CIC of different molecular masses (see below). Upon dissociation of CIC at acid pH, both p and monomeric (m) forms of IgA1 were detected [11, 13].

Mesangial Deposits and CIC: Is the Antigen of Exogenous or Endogenous Origin?

By definition, IC are composed of an antigen and corresponding antibody that may also bind complement components. The nature of antigen(s) in CIC and mesangial deposits of IgAN patients has remained an enigma since the discovery of this disease. The possible involvement of exogenous antigens stems from both clinical and experimental observations. The onset of macroscopic hematuria shortly after an upper respiratory or intestinal tract infection frequently heralds the clinical manifestations. Furthermore, extended feeding of mice with dietary proteins leads to their mesangial deposition, accompanied by IgA [14]. Collectively, these findings suggested that exogenous antigens of microbial or food origin may play an essential role, as components of CIC, in the pathogenesis of IgAN. Consequently, extensive studies of such antigens deposited in the mesangium commenced. A brief list of potential antigens that have been evaluated exemplifies their obvious heterogeneity. Positive staining in some studies, but not in others, was observed for antigens of herpes simplex virus 1 and 2, cytomegalovirus, Epstein-Barr virus (EBV), hepatitis B virus, adenovirus, soybean protein, casein, and bovine whey proteins [for review, see 15]. Therefore, these approaches did not convincingly identify a uniformly encountered exogenous antigen as a component of the mesangial deposits and/or CIC. Endogenous glomerular antigens such as basement membrane collagens have been considered as components of in situ-formed IC in IgAN [16]. However, other reports questioned their participation [17].

Molecular Aberrancy of IgA1 Molecules in IgAN

The possibility that IgAN is a disease associated with a molecular aberrancy and/or defect of IgA1 was suggested by a reduced reactivity of IgA in the sera of IgAN patients with jacalin, a lectin [18] specific for O-linked glycan side chains containing N-acetylgalactosamine (GalNAc) and galactose (Gal) linked by β1,3-glycosidic bond. However, this study did not provide information elucidating the molecular basis of this reduced reactivity.

Shortly after Andre et al. [18] observation that the serum IgA from patients with IgAN exhibited diminished binding to jacalin and our studies [12, 13, 19], we proposed at the International Symposium on IgA Nephropathy in 1992 and published a year later that the Gal deficiency is restricted to O-linked glycan chains attached to the HR of IgA1. Furthermore, in 2001, two groups reported that IgA1 molecules in the mesangial immune deposits are aberrantly glycosylated [20, 21]. This structural variation greatly influences the tissue distribution of such Gal-deficient molecules [22]. It may surprise many nephrologists as well as immunologists that humans daily produce more IgA than all other immunoglobulin isotypes combined [7, 23, 24]. Approximately two thirds of IgA are produced in mucosal
tissues, particularly in the intestinal tract, and are selectively transported into external secretions. Plasma IgA originates in the bone marrow and to a lesser extent in the spleen and lymph nodes. The lower plasma level of IgA than IgG is the result of its more rapid catabolism (the half-life of IgA is 5–6 vs. 20–25 days for IgG).

Experiments with both mice and primates clearly indicated that the liver is the major organ involved in the catabolism of IgA and other glycoproteins [25–28]. The asialoglycoprotein receptor (ASGP-R) expressed on hepatocytes interacts with terminal Gal or GalNAc [25, 28]. We have demonstrated that IgA molecules of both subclasses are also bound, internalized, and catabolized by human hepatoma cell lines [28]. Therefore, the loss of terminal Gal on O-linked glycans should not profoundly influence these processes because interactions between ASGP-R and GalNAc of the IgA1 HR would not be impaired. This apparent contradiction was explained by detailed analyses of CIC [12, 13]. Gal-deficient IgA was present exclusively in IC. It was bound to IgG with specificity to GalNAc as demonstrated by inhibition of the re-association of IC with GalNAc-containing compounds. Consequently, terminal GalNAc residues with the potential to interact with the ASGP-R are covered by specific antibodies that prevent such interactions [12, 13, 29].

The most striking structural feature that differentiates human IgA1 from immunoglobulins of all other isotypes is its unique HR (fig. 1). Comparative evolutionary studies of IgA HR of many species [7, 30] clearly indicate that a relatively recent insertion of a gene segment encoding for an additional thirteen amino acids occurred into the phylogenetically older IgA2 gene. The origin of this insertion is unknown, although by its amino acid composition and sequence, and the presence of O-linked glycans, the human IgA1 HR remotely resembles mucin. However, other properties, such as susceptibility to proteolytic enzymes of bacterial origin [31], are distinct and absolutely unique. It should be stressed that only in humans and hominoid primates, such as chimpanzees and gorillas, IgA1 chains contain HR with minor differences in their primary structures. The structural or functional advantage (or disadvantage) conferred by the HR insertion into the hominoid primate H chains remains obscure.

Our studies of the antigenic determinants on human IgA1 that are recognized by naturally occurring antibodies revealed the dominant role of O-linked glycan moieties [12, 13]. Thus, the enzymatic removal of O-linked glycans by endoglycosidases resulted in the reduction or loss of reactivity with antibodies, and the reformation of acid-dissociated IC was partially inhibited by Gal-deficient IgA1 or other glycoproteins bearing O-linked glycans with terminal GalNAc. However, the exact localization and relative involvement of individual O-linked glycan chains have not been precisely determined. Deficiency of Gal resulting in the exposure of GalNAc (either as the terminal glycan or perhaps its si-
Furthermore, cells patients with IgAN than in healthy controls with HAA. Variants 1 and 2 on serum IgA1 are more common in patients with IgAN than in healthy controls. Variant 2 reacts with this lectin only after neuraminidase treatment to remove sialic acid (SA); and variants 3 and 4 do not react with HAA. Obviously, additional experiments addressing exposure to anti-glycan antibodies and the reactivity with GalNAc-specific naturally occurring antibodies has not been fully explored.

Anti-GalNAc antibodies of the IgG isotype are present in sera of all IgAN patients and healthy individuals, as well as in cord blood or intravenous gammaglobulin preparations [12, 13, 36, 38, 41–44]. Furthermore, cells secreting antibodies specific for Gal-deficient IgA1 can be easily detected and enumerated in peripheral blood from IgAN patients and, at lower frequency from normal individuals, by ELISPOT or immunofluorescence. Antibodies specific for Gal-deficient human IgA1, but not IgA2, are present in IgG from sera of many phylogenetically diverse vertebrate species, including pigs, rabbits, cows, donkeys, goats, sheep, mice, and rats [36]. The origin of these naturally occurring antibodies remains unclear. However, many microorganisms (both viruses and bacteria) express GalNAc-containing glycan side chains on their surface structures and are likely to induce antibodies that cross-react with analogous structures on IgA1 or other cell-associated glycoproteins.

GalNAc-Specific Antibodies

Although Gal-deficiency of IgA1 molecules in CIC and mesangial deposits in IgAN patients has been reported by several investigators [for reviews, see 2–4, 39, 40] our previous contention that Gal-deficient IgA1 is an antigen recognized by GalNAc-specific naturally occurring antibodies has not been fully explored.

Molecular Basis of Gal Deficiency in the HR of IgA1

O-linked glycans of IgA1 are synthesized in a stepwise manner, beginning with attachment of GalNAc to Ser or Thr, catalyzed by UDP-N-acetylgalactosaminyl-transferase 2 (GalNAcT2) [45] (fig. 2). The O-glycan chain is then extended by the attachment of Gal to GalNAc. The addition of Gal is mediated by core 1 β1,3-galactosyltransferase (CIβ3GalT1) that transfers Gal from UDP-Gal to a GalNAc residue [46]. The stability of this enzyme depends on its interaction with a chaperone, Cosmc (CIβ3GalT1-specific molecular chaperone) [46–49]. In the absence of Cosmc, the CIβ3GalT1 protein is degraded rapidly, thereby resulting in undergalactosylation of GalNAc in O-linked glycans. The glycan structure is completed by sialylation transfersases (specific for α2,3-Gal and α2,6-GalNAc) that attach negatively charged SA to the Gal or GalNAc.

**Fig. 2.** Biosynthesis and variants of O-glycans in the HR of human IgA1. Variant 1 reacts with GalNAc-specific lectins, such as HAA; variant 2 reacts with this lectin only after neuraminidase treatment to remove sialic acid (SA); and variants 3 and 4 do not react with HAA. Variants 1 and 2 on serum IgA1 are more common in patients with IgAN than in healthy controls [12, 13, 37, 70]; variants 3 and 4 on the serum IgA1 are more common in healthy controls than in patients with IgAN [71].
residues. Sialylation of GalNAc in IgA1-secreting cells is mediated by a GalNAc-specific α2,6-sialyltransferase, ST6GalNAcII [50]. If SA is linked to GalNAc prior to attachment of Gal, this ‘premature’ sialylation precludes subsequent attachment of a Gal residue [40, 50, 51]. Thus, the relative activity of ST6GalNAcII and C1β3GalT1/ Cosmc can directly influence the glycosylation of IgA1.

Our recent studies with EBV-immortalized cell lines from peripheral blood lymphocytes of patients with IgAN and healthy controls confirmed the above-described pathways in the IgA1-secreting cells [38]. Furthermore, detailed analysis of enzymatic activities in the cell lines from patients with IgAN indicated an imbalance in the activities of the pertinent glycosyltransferases. The C1β3GalT1 activity was significantly lower and the GalNAc-specific α2,6-sialyltransferase activity was significantly higher. Studies of the aberrant glycosylation in IgAN represent a promising field with a potentially great impact on the future care of patients [52].

**Generation of IC and Their Functional Activities**

Because Gal-deficient IgA1 is predominant in high-molecular-mass fractions of serum whereas anti-GalNAc antibodies are easily detectable in their free form, it is obvious that CIC present in the patients’ sera are formed in the antibody-excess zone. We stress that our studies focused on CIC that contain GalNAc-specific antibodies of the IgG isotype and therefore did not fully consider CIC containing other isotypes that probably differ in both physicochemical and biological properties. Nevertheless, biological effects of CIC in vivo are likely to depend on the portion of CIC that exhibit either stimulatory or inhibitory effects on cultured human mesangial cells [53]. This, in turn, might reflect the composition (including immunoglobulin isotype), charge, size, tissue and body fluid distribution, and reactivity with relevant cellular receptors. The latter point is of particular importance: terminal Gal or GalNAc on glycoprotein molecules of limited size is recognized and internalized by the hepatic ASGP-R. Although we proposed that anti-GalNAc antibodies inhibit the removal of Gal-deficient IgA1 in the liver, there are still free terminal GalNAc residues available, as evidenced by their HAA reactivity [12, 13]. Therefore, it is likely that the size of CIC and/or inaccessibility of GalNAc to ASGP-R due to the potential hindrance conferred by bound IgG prevent effective CIC clearance and increases their elimination through the kidneys [54]. Indeed, IgA-containing IC are present in the urine of IgAN patients in a significantly higher amount than in the urine of patients with other renal diseases with comparable proteinuria, and in healthy controls [54]. With disease progression, proteinuria increases and is often non-selective, so that high-molecular-weight proteins (such as immunoglobulins) cross the glomerular capillary wall and appear in the urine. These observations indicate that kidneys of IgAN patients are exposed to a high load of IgA1-containing CIC that are excreted in the urine by filtration across the damaged glomerular barrier. Indeed, their urinary levels positively correlated with proteinuria (p < 0.001). These CIC have a molecular mass of 650–850 kDa.

To evaluate the biological activity of various forms of IgA1- and IgG-containing IC, we developed a model with cultured human mesangial cells. First, we assessed binding of IgA1, Gal-deficient IgA1, and IgA1-containing CIC to these cells. Gal-deficient IgA1 bound better than did normally glycosylated IgA1. IgA1-containing IC from patients with IgAN bound with higher affinity to mesangial cells than did uncomplexed IgA1 [29]. This binding was mediated by a receptor different from CD89, ASGP-R, and the polymeric immunoglobulin receptor [29, 55, 56].

To study the activation of cultured human mesangial cells by IgA1 and IgA1-containing IC, we measured changes in cellular proliferation. We used IgA1 IC from sera of IgAN patients and healthy controls purified by size-exclusion chromatography [29]. The incubation of mesangial cells with serum fractions with Mr 800–900 kDa, rich with Gal-deficient IgA1, stimulated proliferation, while fractions with smaller complexes were inhibitory [29, 53]. Furthermore, CIC containing larger molecular mass fractions isolated from serum of an IgAN patient collected during an episode of macroscopic hematuria stimulated proliferation of mesangial cells more than did CIC obtained during a subsequent quiescent phase. To examine the role of IgA, we removed IgA1 from the serum before fractionation. The resultant IgA1-depleted fractions were devoid of stimulatory IgA1-CIC. Sera of IgAN patients were also fractionated after addition of desialylated Gal-deficient pIgA1 to form additional IC. Supplementation with a small quantity of this IgA1 increased cellular proliferation in assays using serum fractions of Mr ≥800–900 kDa; uncomplexed IgA1 did not significantly affect MC proliferation [53]. In contrast, supplementation with a larger quantity of this IgA1 inhibited cellular proliferation in assays using serum fractions of Mr 700–800 kDa. In summary, these findings suggest that CIC containing aberrantly glycosylated IgA1 affect proliferation of mesangial cells in vitro and thus likely play a role in the pathogenesis of IgAN.
A growing body of evidence indicates that glycan moieties on free or cell-bound glycoproteins play essential roles in many biological processes and functions and that their alterations are demonstrable in a number of human diseases [57–61]. Interestingly, such aberrancies are most frequently manifested by a deficiency of Gal on N- and/or O-linked glycans (table 1). In diseases associated with chronic inflammation such as rheumatoid arthritis, systemic lupus erythematosus, juvenile onset rheumatoid arthritis, Sjögren syndrome, inflammatory bowel diseases, periodontal disease, tuberculosis, and infection with the human immunodeficiency virus [61–65], IgG molecules display Gal deficiency on N-linked glycans of IgG molecules. This Gal deficiency, that appears to be associated with altered activity of β1,4 Gal transferase, results in the exposure of GlcNAc, which, in turn, leads to the potent activation of complement by the lectin pathway with all its inflammatory consequences [64, 65]. This process ensues because the mannan-binding lectin also interacts with GlcNAc [65].

A rare disease, Tn syndrome, also termed mixed field polyagglutination, is characterized by the deficiency of Gal on O-linked glycans in a broad spectrum or a single type of blood elements including erythrocytes, lymphocytes, monocytes, platelets, granulocytes, and/or platelets [66–69].

Molecular studies of involved cell populations revealed a Gal deficiency on cell-surface glycoproteins resulting in the exposure of Tn antigen that consists of three vicinal GalNAc residues [66]. The Tn epitope is recognized by naturally occurring, complement-activating ubiquitous IgM antibodies induced by commensal Gram-negative bacteria. As a result of such an interaction, agglutination of afflicted blood elements and their consequential lysis induce anemia and thrombocytopenia. Importantly, such clinical manifestations become apparent only in a very small proportion of such individuals. This is due to the finding that the percentage of Gal-deficient blood elements must be greater than 10%; otherwise, the clinical symptoms of Tn syndrome do not develop. Despite the structural differences in the epitopes of Tn antigen on blood elements and the HR of IgA1, as well as the isotypes of corresponding anti-GalNAc antibodies, both diseases display similarities in their structural basis and pathogenetic mechanisms. It is apparent that in patients with IgAN the proportion of Gal-deficient versus normally glycosylated IgA1 and the level and isotype of GalNAc-specific antibodies resulting in the formation of nephritogenic CIC play a decisive role in the manifestation and severity of the disease.

Extensive evaluations of sera from IgAN patients and controls with respect to the reactivity with GalNAc-specific lectins clearly demonstrated distinct patterns with

<table>
<thead>
<tr>
<th>Disease</th>
<th>Afflicted molecules or cells</th>
<th>Deficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgA nephropathy</td>
<td>HR IgA1</td>
<td>Gal in O-linked glycans</td>
</tr>
<tr>
<td>Tn syndrome</td>
<td>erythrocytes, lymphocytes, monocytes, platelets, granulocytes</td>
<td>Gal in O-linked glycans – exposed Tn antigen</td>
</tr>
<tr>
<td>Sjögren syndrome</td>
<td>IgG, IgA1, IgA2</td>
<td>Gal in N- and/or O-linked</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Juvenile onset rheumatoid arthritis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systemic lupus erythematosus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crohn’s disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ulcerative colitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Periodontal disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuberculosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human immunodeficiency virus infection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wiscott-Aldrich syndrome</td>
<td>B, T lymphocytes, platelets</td>
<td>GlcNAc in O-linked chains</td>
</tr>
<tr>
<td>Paroxysmal nocturnal hemoglobinuria</td>
<td>glycosylphosphatidylinositol on erythrocytes, T cells, granulocytes</td>
<td>GlcNAc</td>
</tr>
</tbody>
</table>

Table 1. Glycan deficiencies in patients with various diseases [summarized from refs. 9, 10, 16, 33, 52–58, 60–65]
markedly higher Gal deficiency in the former population [13, 37, 70]. However, the lectin displayed remarkably varied binding, probably associated with the current stage of the disease. Although present at statistically significantly lower levels, binding to the lectin probe was also observed using sera from the control population, suggesting that a very small proportion of IgA molecules in apparently healthy individuals may also be Gal-deficient. Again, this finding stresses the importance of the proportion of the antigen (Gal-deficient IgA) and antibodies in the generation of high-molecular-mass nephritogenic IgA CIC.

Conclusion

Identification of Gal-deficient IgA1 as an antigen and of GalNAc-specific IgG and/or IgA1 as an antibody involved in the formation of nephritogenic IC has potentially important implications for the pathogenesis of IgAN (fig. 3), and ultimately its treatment. As a consequence of infection, a portion of IgA1 molecules produced by plasma cells display a deficiency of Gal on O-linked glycans leading to the un-masking of novel GalNAc-associated epitopes. These epitopes react with corresponding naturally occurring antibodies and, depending on the antigen (pIgA1) to antibody proportions, form CIC of variable molecular masses. Large CIC cannot enter through endothelial fenestrae overlying the space of Disse to reach the asialoglycoprotein receptor (ASGP-R) on hepatocytes, but are able to pass through the larger fenestrae in glomerular capillaries overlying the mesangium. These deposited complexes induce glomerular injury and alter the urinary proteome.

Fig. 3. A model of pathogenesis of IgAN. A portion of IgA1 molecules produced by plasma cells in patients with IgAN is Gal-deficient and is recognized by anti-glycan IgG (or IgA1) antibodies [12, 13, 38, 72]. The formed IC due to their size cannot enter the space of Disse to reach the asialoglycoprotein receptor (ASGP-R) on hepatocytes, but are able to pass through the larger fenestrae in glomerular capillaries overlying the mesangium. These deposited complexes induce glomerular injury and alter the urinary proteome.

Acknowledgments

We thank Rose Kulhavy, Huong L. Vu, Rhubell Brown, Stacy Hall, Wen-Qiang Huang, Claretha R. Nichols, Candace Kirksey, Nagaraju Sarabu, Sandeep Anreddy, Lokesh Thakkalapati, and Cristy Salazar for their technical expertise, and Catherine V. Barker and Susan Y. Woodford for collection of the clinical samples. This work was supported by grants DK78244, DK61525, and DK71802 from the NIH and by General Clinical Research Center of the University of Alabama at Birmingham (M01 RR00032) (USA), and Research projects MSMT-0021620819, MSM-0021620812, and KJ-586206106 (Czech Republic).
References


Mestecky et al.


